Recent developments help the defense of drug companies in 10b-5 cases.
作者信息
Salpeter A N, Hutchins H
出版信息
Food Drug Law J. 1996;51(3):345-53.
PMID:11797711
Abstract
摘要
相似文献
1
Recent developments help the defense of drug companies in 10b-5 cases.
Food Drug Law J. 1996;51(3):345-53.
2
The application of the patent laws to the drug approval process.
Food Drug Law J. 1997;52(4):345-55.
3
A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Seton Hall Law Rev. 2009;39(2):559-603.
4
Maine law requires drug companies to provide clinical trial data.
J Natl Cancer Inst. 2005 Sep 7;97(17):1246. doi: 10.1093/jnci/dji299.
5
The problem of new uses.
Yale J Health Policy Law Ethics. 2005 Summer;5(2):717-39.
6
Lawsuits anticipated on generic biologicals front.
Nat Biotechnol. 2003 Jul;21(7):721-2. doi: 10.1038/nbt0703-721.
7
Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Drug Discov Today. 2004 Jun 15;9(12):509-12. doi: 10.1016/S1359-6446(04)03067-3.
8
Path to approval proves rocky for copycat biodrugs.
Nature. 2005 Nov 10;438(7065):154-5. doi: 10.1038/438154a.
9
Sandoz sues FDA over delay in first biogeneric approval.
Nat Biotechnol. 2005 Nov;23(11):1327-8. doi: 10.1038/nbt1105-1327.
10
The FDA and "privatization"--the drug approval process.
Food Drug Law J. 1995;50 Spec:203-25.
Zotero 插件